Iridex Introduces New Research and Showcases Five Events at the AGS Meeting
March 02 2023 - 9:00AM
Iridex Corporation (NASDAQ: IRIX), a provider of innovative
ophthalmic laser-based medical products for the treatment of
glaucoma and retinal diseases, today announced Part 2 of the
evidence-based guidelines series for MicroPulse Transscleral Laser
Therapy (TLT) has been published in Clinical Ophthalmology1 by the
international consensus panel of ten glaucoma experts. The
publication will be available at booth #5 at the 2023 meeting of
the American Glaucoma Society (AGS), March 2 -5 in Austin, Texas.
More info on the consensus and Iridex at AGS:
Consensus Panel RecommendationsPart 2
recommendations address anesthesia, surgical technique,
post-operative care, expected outcomes, settings adjustment, and
enhancements and retreatments.2 Part 1 of the consensus
recommendations, published in 2021, focused on patient dosimetry
and patient selection.2 The recommendations, which are confirmed as
100% consensus among the experts, are the result of a complete
analysis of MicroPulse TLT clinical, technical, and practical
experience to date.
“As physicians gathered further experience and conducted
additional research on MicroPulse TLT, a better understanding of
all aspects of the treatment helped improve the procedure and
optimize outcomes,” said Tomas Grippo, MD, co-chair of the
International MicroPulse TLT Consensus Panel. “We are pleased to
provide additional guidelines for a treatment we have found to be
safe and effective for many types and severities of glaucoma.”
The recommendations provide a valuable foundation for learning
how to maximize the safety and effectiveness of this non-incisional
procedure performed with the Cyclo G6® Laser and revised MicroPulse
P3® Delivery Device. The revised device has improved ergonomics
that support more stable positioning during treatment and
facilitates a more posterior application of laser energy, keeping
it farther from anterior segment structures.2,3
Copies of the paper will be distributed free at the Iridex
booth. To watch the expert panel discuss its findings, visit
www.iridex.com/consensus to view Part 1 and Part 2 of the consensus
webinar series, or download the white paper here.
Hear Dr. Syril Dorairaj’s e-poster on prospective
MicroPulse TLT dosimetry research outcomes
Dr. Syril Dorairaj and colleagues present their e-poster,
“Clinical Outcomes of MicroPulse Transscleral Laser Therapy: A
Prospective Cohort Study.” Check the AGS program for more
details.
Demo our Sweep Management Software for MicroPulse
TLTMicroPulse TLT is a versatile, non-incisional and
repeatable procedure for the treatment of glaucoma performed with
the Iridex Cyclo G6® Laser System and MicroPulse P3® Delivery
Device. The Cyclo G6 now provides Sweep Management Software, which
allows surgeons to tailor an optimized therapeutic dose for
delivering MicroPulse TLT. Demos are available at the Iridex booth
where physicians can learn how to improve their surgical technique
and consistency in application.
Help us celebrate! We invite AGS attendees to
stop by the Iridex booth #5 to sign a super-sized card to
congratulate Dr. Douglas Gaasterland, the AGS Innovator Award
recipient, for his pioneering contributions to glaucoma and
ophthalmology. We are honored to have collaborated with Dr.
Gaasterland in his pioneering work on the advancement of
transscleral cyclophotocoagulation and the development of the
Iridex G-Probe®.
Join our next Iridex Academy webinar on MicroPulse
TLT Register for our March Iridex Academy webinar at
iridex.com/training to join host Dr. Brian Francis for an
advanced peer-to-peer surgeon forum on MicroPulse TLT.
References
- Grippo TM, et al. Evidence-based consensus guidelines series
for micropulse transscleral laser therapy - surgical technique,
post-operative care, expected outcomes and
retreatment/enhancements. Clin Ophthalmol 2023;17:71-83.
- Grippo TM, et al. Evidence-based consensus guidelines series
for micropulse transscleral laser therapy: Dosimetry and patient
selection. Clin Ophthalmol 2022;16:1837-1846.
- Checo L, et al. Prospective comparison of different energy
parameters of micropulse transscleral laser therapy. Presented at
American Glaucoma Society Annual Meeting; 2022; Nashville, TN.
About IridexIridex is a worldwide leader in
developing innovative and versatile laser-based medical systems,
delivery devices, and consumable instrumentation for the
ophthalmology market. The Company’s proprietary MicroPulse®
technology delivers a differentiated treatment that provides safe,
effective, and proven therapy for targeted sight-threatening eye
conditions. Iridex’s products are used to treat glaucoma, diabetic
macular edema, and other retinal diseases. Iridex products are sold
in the United States and Germany through a direct sales force and
in more than 100 countries through a network of independent
distributors. For more information, visit
https://www.iridex.com/.
Iridex Media ContactJamie
HallPRECISIONeffect724.417.0167jamie.hall@precisionvh.com
IRIDEX (NASDAQ:IRIX)
Historical Stock Chart
From Jul 2024 to Aug 2024
IRIDEX (NASDAQ:IRIX)
Historical Stock Chart
From Aug 2023 to Aug 2024